Myomo vs Utah Medical Products
Myomo reported revenue of $41 million in fiscal 2025, about the same as Utah Medical Products' $38 million in fiscal 2025. Myomo's revenue grew 25.7% in its latest year, and Utah Medical Products' fell 5.8%. Myomo had an operating margin of -35.2%, against 29.6% at Utah Medical Products. Free cash flow was −$16 million at Myomo and $14 million at Utah Medical Products.
Side by side
| Myomo | Utah Medical Products | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $41M | $38M |
| Revenue growth | 25.7% | −5.8% |
| Revenue growth a year, last 5 years | 40.0% | −1.8% |
| Gross margin | 65.7% | 57.1% |
| Operating margin | −35.2% | 29.6% |
| Net margin | −38.0% | 29.3% |
| Free cash flow | −$16M | $14M |
| Free cash flow margin | −39.7% | 37.2% |
| Return on capital | — | 26.8% |
| Net debt to EBITDA | — | −6.0x |
| Dividends and buybacks | $0M | $12M |
| Change in diluted share count | 10.8% | −7.5% |
| Last close | $0.84 | $70.96 |
| P/E at the last close | — | 21.2× |
| Insider trades, last 12 months | bought $439,324, sold $102,893 | — |
| Piotroski F-score | 3 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
MyomoUtah Medical Products
Operating margin
Percent of revenue
MyomoUtah Medical Products
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MyomoUtah Medical Products
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Myomo and Utah Medical Products pages.